Kaitoh Atherectomy System: Peripheral Artery Revascularization of Stenotic/Restenotic Disease Using the Atherectomy System in the Peripheral Arteries

Status: Completed
Location: See all (2) locations...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This is a prospective, multi-center and single-arm clinical study to assess the initial safety and effectiveness of the Kaitoh Atherectomy System for the treatment of de novo and/or restenotic lesion(s) in the peripheral arteries.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age ≥18 years old

• Rutherford Classification: 3-5 in target limb; Rutherford Classification 3 subjects may be enrolled but will be capped to a limit of 20% of the total enrollment (no more than two Rutherford Class 3 subjects may be enrolled into the study).

• Able and willing to provide informed consent, and comply with follow-up visits at both 30 days and 180 days (6 months)

• Able to comply with antiplatelet therapy as required

• Reference Vessel Diameter is ≥2.0 mm and ≤4.0 mm

• Target lesion length is ≤150 mm

• De novo or restenotic target lesion(s) (except for in-stent restenotic lesion) with stenosis ≥70%, by visual estimation, in a single limb in a single native vessel

• Inflow artery is patent, free from significant lesion stenosis (≥50% stenosis is considered significant) as visually confirmed by angiography. Note: Successful inflow artery treatment is allowed during the index procedure. Successful inflow artery treatment is defined as attainment of residual diameter stenosis ≤50% without major vascular complications (absence of flow limiting dissection, embolic event)

• Guidewire has successfully crossed the target lesion(s) within the true lumen

Locations
Other Locations
New Zealand
Auckland Hospital
Auckland
Waikato Hospital
Hamilton
Time Frame
Start Date: 2023-08-07
Completion Date: 2025-08-05
Participants
Target number of participants: 9
Treatments
Experimental: Kaitoh Atherectomy System
Eligible participants will undergo atherectomy using the Kaitoh Atherectomy System.
Sponsors
Leads: Terumo Medical Corporation

This content was sourced from clinicaltrials.gov